NASDAQ:VCEL Vericel (VCEL) Stock Price, News & Analysis → Beta testers blew this thing up (From Prosper Trading Academy) (Ad) Free VCEL Stock Alerts $41.71 -0.58 (-1.37%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$41.16▼$42.5450-Day Range$41.71▼$51.5352-Week Range$30.18▼$53.05Volume504,565 shsAverage Volume486,395 shsMarket Capitalization$2.03 billionP/E RatioN/ADividend YieldN/APrice Target$46.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Vericel alerts: Email Address Vericel MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside12.2% Upside$46.80 Price TargetShort InterestBearish9.94% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.00Based on 7 Articles This WeekInsider TradingSelling Shares$1.72 M Sold Last QuarterProj. Earnings Growth422.22%From $0.09 to $0.47 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.79 out of 5 starsMedical Sector831st out of 913 stocksBiological Products, Except Diagnostic Industry145th out of 152 stocks 2.5 Analyst's Opinion Consensus RatingVericel has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVericel has only been the subject of 2 research reports in the past 90 days.Read more about Vericel's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.94% of the outstanding shares of Vericel have been sold short.Short Interest Ratio / Days to CoverVericel has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.Change versus previous monthShort interest in Vericel has recently increased by 4.32%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVericel does not currently pay a dividend.Dividend GrowthVericel does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VCEL. Previous Next 2.2 News and Social Media Coverage News SentimentVericel has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Vericel this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 1 people have added Vericel to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vericel insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,721,471.00 in company stock.Percentage Held by InsidersOnly 7.20% of the stock of Vericel is held by insiders.Read more about Vericel's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Vericel are expected to grow by 422.22% in the coming year, from $0.09 to $0.47 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vericel is -4,166.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vericel is -4,166.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVericel has a P/B Ratio of 8.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vericel's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and finds hot stocks that you probably have never even heard of… …it recommends the best potential strategy to use on the names it finds (with historical data to prove it)Click Here To Read More About This Game Changing AI Tool About Vericel Stock (NASDAQ:VCEL)Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.Read More VCEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VCEL Stock News HeadlinesJune 15 at 8:46 AM | insidertrades.comVericel Co. (NASDAQ:VCEL) CEO Sells $772,100.00 in StockJune 15 at 8:48 AM | americanbankingnews.comVericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo Sells 17,500 SharesJune 11, 2024 | globenewswire.comVericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024May 22, 2024 | globenewswire.comVericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024May 11, 2024 | markets.businessinsider.comVericel’s Strong Q1 Performance and Growth Potential Affirm Buy RatingMay 10, 2024 | bloomberg.comVericel Finds Gem in Cartilage Repair: Vanguards of Health CareMay 9, 2024 | markets.businessinsider.comCritical Insights From Vericel Analyst Ratings: What You Need To KnowMay 9, 2024 | finance.yahoo.comVericel First Quarter 2024 Earnings: Beats ExpectationsMay 9, 2024 | finance.yahoo.comVericel Corp (VCEL) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ...May 8, 2024 | msn.comVCEL Stock Earnings: Vericel Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | finance.yahoo.comVericel Corp (VCEL) Surpasses Q1 Revenue Forecasts with Strong Growth in Core MarketsMay 8, 2024 | seekingalpha.comVericel Corporation 2024 Q1 - Results - Earnings Call PresentationMay 8, 2024 | finanznachrichten.deVericel Corporation: Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial GuidanceMay 8, 2024 | msn.comVericel GAAP EPS of -$0.08 beats by $0.03, revenue of $51.3M beats by $2.23MMay 8, 2024 | globenewswire.comVericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial GuidanceMay 7, 2024 | markets.businessinsider.comWhat Wall Street expects from Vericel's earningsMay 7, 2024 | msn.comVericel Q1 2024 Earnings PreviewApril 26, 2024 | finance.yahoo.comHere's Why Shareholders May Want To Be Cautious With Increasing Vericel Corporation's (NASDAQ:VCEL) CEO Pay PacketApril 24, 2024 | globenewswire.comVericel to Report First-Quarter 2024 Financial Results on May 8, 2024April 21, 2024 | nz.finance.yahoo.comVericel Corporation (VCEL) stock historical prices & data – Yahoo FinanceApril 17, 2024 | money.usnews.comVericel CorpApril 13, 2024 | finance.yahoo.comVericel Corporation (NASDAQ:VCEL) On The Verge Of Breaking EvenApril 7, 2024 | nasdaq.comCommit To Buy Vericel At $25, Earn 9% Annualized Using OptionsMarch 27, 2024 | markets.businessinsider.comAnalyst Scoreboard: 5 Ratings For VericelMarch 3, 2024 | ca.finance.yahoo.comVCEL Oct 2024 50.000 callSee More Headlines Receive VCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/17/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VCEL CUSIPN/A CIK887359 Webwww.vcel.com Phone(617) 588-5555Fax617-588-5554Employees314Year Founded1989Price Target and Rating Average Stock Price Target$46.80 High Stock Price Target$55.00 Low Stock Price Target$39.00 Potential Upside/Downside+12.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E Ratio463.44 P/E GrowthN/ANet Income$-3,180,000.00 Net Margins0.22% Pretax Margin0.61% Return on Equity0.21% Return on Assets0.13% Debt Debt-to-Equity RatioN/A Current Ratio5.20 Quick Ratio4.83 Sales & Book Value Annual Sales$197.52 million Price / Sales10.26 Cash Flow$0.02 per share Price / Cash Flow2,399.85 Book Value$4.73 per share Price / Book8.82Miscellaneous Outstanding Shares48,600,000Free Float45,103,000Market Cap$2.03 billion OptionableOptionable Beta1.74 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Dominick C. Colangelo Esq. (Age 60)CEO, President & Director Comp: $1.54MMr. Joseph Anthony Mara Jr. (Age 48)CFO & Treasurer Comp: $750.61kMr. Michael Halpin (Age 62)Chief Operating Officer Comp: $796.91kMr. Sean C. Flynn (Age 50)Chief Legal Officer Comp: $657.01kDr. Jonathan M. Hopper FRCSEd. (Age 62)M.B. Ch.B., Chief Medical Officer Comp: $672.16kMr. Jonathan D. SiegalPrincipal Accounting Officer, VP & Corporate ControllerMr. Eric BurnsVice President of Finance & Investor RelationsMr. Patrick J. FowlerSenior Vice President of Corporate Development & StrategyMr. Patrick HelfrichVice President of Marketing & Commercial StrategyMr. Mike GilliganSenior Vice President of SalesMore ExecutivesKey CompetitorsREGENXBIONASDAQ:RGNXiTeos TherapeuticsNASDAQ:ITOSAlectorNASDAQ:ALECBlack Diamond TherapeuticsNASDAQ:BDTXC4 TherapeuticsNASDAQ:CCCCView All CompetitorsInsiders & InstitutionsDominick ColangeloSold 17,500 sharesTotal: $772,100.00 ($44.12/share)Kopp Family Office LLCSold 1,800 shares on 6/3/2024Ownership: 0.942%Comerica BankBought 15,376 shares on 5/17/2024Ownership: 0.445%Castleark Management LLCSold 17,770 shares on 5/17/2024Ownership: 0.268%California State Teachers Retirement SystemSold 2,600 shares on 5/16/2024Ownership: 0.094%View All Insider TransactionsView All Institutional Transactions VCEL Stock Analysis - Frequently Asked Questions Should I buy or sell Vericel stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VCEL shares. View VCEL analyst ratings or view top-rated stocks. What is Vericel's stock price target for 2024? 6 analysts have issued 1-year target prices for Vericel's shares. Their VCEL share price targets range from $39.00 to $55.00. On average, they anticipate the company's share price to reach $46.80 in the next year. This suggests a possible upside of 12.2% from the stock's current price. View analysts price targets for VCEL or view top-rated stocks among Wall Street analysts. How have VCEL shares performed in 2024? Vericel's stock was trading at $35.61 at the beginning of the year. Since then, VCEL shares have increased by 17.1% and is now trading at $41.71. View the best growth stocks for 2024 here. When is Vericel's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our VCEL earnings forecast. How were Vericel's earnings last quarter? Vericel Co. (NASDAQ:VCEL) posted its quarterly earnings results on Wednesday, May, 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.03. The biotechnology company had revenue of $51.28 million for the quarter, compared to analyst estimates of $49.07 million. Vericel had a net margin of 0.22% and a trailing twelve-month return on equity of 0.21%. The firm's quarterly revenue was up 25.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.16) earnings per share. What ETFs hold Vericel's stock? ETFs with the largest weight of Vericel (NASDAQ:VCEL) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), WisdomTree BioRevolution Fund (WDNA), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI) and Syntax Stratified SmallCap ETF (SSLY).Direxion Daily S&P Biotech Bull 3x Shares (LABU). What guidance has Vericel issued on next quarter's earnings? Vericel issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $238.0 million-$242.0 million, compared to the consensus revenue estimate of $239.2 million. What is Nick Colangelo's approval rating as Vericel's CEO? 6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Vericel own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA). Who are Vericel's major shareholders? Vericel's stock is owned by many different retail and institutional investors. Top institutional shareholders include Brown Capital Management LLC (10.19%), Vanguard Group Inc. (7.06%), Conestoga Capital Advisors LLC (4.82%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (2.11%), William Blair Investment Management LLC (1.74%) and Congress Asset Management Co. MA (1.73%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Jonathan Siegal, Michael Halpin, Robert L Md Zerbe, Sean C Flynn and Steven C Gilman. View institutional ownership trends. How do I buy shares of Vericel? Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VCEL) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vericel With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.